From: Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France
Diabetic patients | 25,458 | ||
---|---|---|---|
2 Measurements of creatinine clearance and 2 Measurements of urinary protein within a one-year time frame | 2,109 | 8,3% | |
OR | At least one record associated with a long term condition “chronic nephropathy and primitive nephrotic syndrom” and at least one ICD 10 code related to chronic kidney failure | 127 | 0,5% |
OR | At least one prescription dispensing of treatment from the following list associated to a nephrologist visit: ACE-I (Angiotensin converting enzyme inhibitors) and A2RA (Angiotensin II receptor antagonists) in association, phosphorus chelators (*), polystyrene sulfonate (**), Angiotensin converting enzyme (ACE) inhibitors, | 496 | 1,9% |
OR | At least two dispensings with an interval from 30 to 365 days of a conbination of following treatment: ACE-I, A2RA, phosphorus chelators (*), polystyrene sulfonate (**) | 170 | 0,7% |
Total number of patients with a chronic kidney failure (CKF) (Declining Renal Function) | 2,535 | 10,0% | |
Patients with terminal CKF: patients with a CKF and…: | |||
At least 2 records associated with a CCAM code related to dialyse within a One-week time period | 67 | 0,3% | |
OR | At least 2 prescription dispensings of erythropoietin AND 2 prescriptions dispensing of phosphorus chelators within a 45 days-time period | 22 | 0,1% |
Total number of patients with a terminal CKF | 80 | 0,3% | |
Patients with severe CKF: patients with a CKF… | 585 | 2,3% | |
At least 2 prescription dispensings of erythropoietin | 470 | 1,8% | |
OR | At least 2 prescription dispensings of phosphorus chelators | 140 | 0,5% |
OR | At least 4 nephrologist visits within 12-months time frame | 58 | 0,2% |
Total number of patients with a severe CKF | 585 | 2,3% | |
Patients with moderate CKF: Patients with a CKF not defined as severe or terminal | |||
Total number of patients with moderate CKF | 1,870 | 7,3% |